Skip to main content
Erschienen in: Current Infectious Disease Reports 11/2019

01.11.2019 | Female Genital Tract Infections (J Sobel, Section Editor)

Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure

verfasst von: Asmita Shukla, J. D. Sobel

Erschienen in: Current Infectious Disease Reports | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Goal was to review epidemiology, pathophysiology, and prevention of post-antibiotic Candida vulvovaginitis (VVC).

Recent Findings

Antibacterial therapy, whether systemic or locally applied to the vagina, represents the single most frequent and predictable cause or triggering mechanism of symptomatic vulvovaginal candidiasis (VVC). Such initiating mechanisms may precipitate sporadic or recurrent episodes of VVC. In spite of this widely recognized association, the exact mechanism whereby antibiotics of all classes cause acute exacerbation of symptomatic vaginal disease remains largely unstudied and therefore largely unknown. Pathophysiology is hypothesized to be reduction or alteration of vaginal microbiome restraints of yeast colonization, proliferation, and expression of virulence characteristics.

Summary

The predictable link between antibiotic use and post-antibiotic VVC affords practitioners an opportunity for timely intervention using selective, convenient antimycotics usually drugs but possibly probiotic measures. Indications and limitation of these steps are discussed.
Literatur
1.
Zurück zum Zitat Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214:15–21.CrossRef Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214:15–21.CrossRef
2.
Zurück zum Zitat Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis. A. Systematic review. Lancet Infect Dis. 2018;18:339–47.CrossRef Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis. A. Systematic review. Lancet Infect Dis. 2018;18:339–47.CrossRef
3.
Zurück zum Zitat Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant, Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRef Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant, Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRef
4.
Zurück zum Zitat lj C. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol. 1964;90:374–8. lj C. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol. 1964;90:374–8.
5.
Zurück zum Zitat Oriel JD, Waterworth PM. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol. 1975;28:403–6.CrossRef Oriel JD, Waterworth PM. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol. 1975;28:403–6.CrossRef
6.
Zurück zum Zitat Iravani A, Richard GA. Amoxicillin-clavulanic acid versus Cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Ag Chemo. 1986;29:107–9.CrossRef Iravani A, Richard GA. Amoxicillin-clavulanic acid versus Cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Ag Chemo. 1986;29:107–9.CrossRef
7.
Zurück zum Zitat Bluestein D, Rutledge C, Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J. 1991;11:319–26.PubMed Bluestein D, Rutledge C, Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J. 1991;11:319–26.PubMed
8.
Zurück zum Zitat MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med. 1993;86:419–24.PubMed MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med. 1993;86:419–24.PubMed
9.
Zurück zum Zitat Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7:182–7.CrossRef Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7:182–7.CrossRef
10.
Zurück zum Zitat Glover DD, Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gyn. 2003;11:157–60.CrossRef Glover DD, Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gyn. 2003;11:157–60.CrossRef
11.
Zurück zum Zitat Spinillo A, Capuzzo E, Acciano A, Santolo AD, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol. 1999;180:14–7.CrossRef Spinillo A, Capuzzo E, Acciano A, Santolo AD, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol. 1999;180:14–7.CrossRef
12.
Zurück zum Zitat Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Interna J Antimicrob Ag. 2002;20:297–300.CrossRef Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Interna J Antimicrob Ag. 2002;20:297–300.CrossRef
13.
Zurück zum Zitat Pirotta MV, Gunn JM, Chondros P. “Not thrush again!” Women’s experience of post-antibiotic vulvovaginitis. General Practice In Action. 2003;179:43–6. Pirotta MV, Gunn JM, Chondros P. “Not thrush again!” Women’s experience of post-antibiotic vulvovaginitis. General Practice In Action. 2003;179:43–6.
14.
Zurück zum Zitat Pirotta M, Gunn J, Chondros P, Grover S, O’Malley P, Hurley S, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ. 2004;27:1–5.CrossRef Pirotta M, Gunn J, Chondros P, Grover S, O’Malley P, Hurley S, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ. 2004;27:1–5.CrossRef
15.
Zurück zum Zitat Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Micro. 2006;44:3213–7.CrossRef Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Micro. 2006;44:3213–7.CrossRef
16.
Zurück zum Zitat Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses. 2006;49:523–4.CrossRef Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses. 2006;49:523–4.CrossRef
17.
Zurück zum Zitat Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261–8.CrossRef Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261–8.CrossRef
18.
Zurück zum Zitat Woods JW, Manning IH Jr, Patterson CN. Monilial infections complicating the therapeutic use of antibiotics. J Am Med Assoc. 1951;145(4):207–11.CrossRef Woods JW, Manning IH Jr, Patterson CN. Monilial infections complicating the therapeutic use of antibiotics. J Am Med Assoc. 1951;145(4):207–11.CrossRef
19.
Zurück zum Zitat Miller CP. New problems in the treatment of infectious diseases. Ann Intern Med. 1951;35(4):763–70.CrossRef Miller CP. New problems in the treatment of infectious diseases. Ann Intern Med. 1951;35(4):763–70.CrossRef
20.
Zurück zum Zitat Waterworth PM. The effect of minocycline on Candida albicans. J Clin Pathol. 1974;27:269–72.CrossRef Waterworth PM. The effect of minocycline on Candida albicans. J Clin Pathol. 1974;27:269–72.CrossRef
21.
Zurück zum Zitat Glover DD, Larsen B. Longitudinal investigation of Candida vaginitis in pregnancy: role of superimposed antibiotic use. Obstet Gynecol. 1998;91:115–8.CrossRef Glover DD, Larsen B. Longitudinal investigation of Candida vaginitis in pregnancy: role of superimposed antibiotic use. Obstet Gynecol. 1998;91:115–8.CrossRef
22.
Zurück zum Zitat McVay LV Jr, Srunt DH. A study of moniliasis in aureomycin therapy. Proc Soc Exp Biol Med. 1951;78(3):759–61.CrossRef McVay LV Jr, Srunt DH. A study of moniliasis in aureomycin therapy. Proc Soc Exp Biol Med. 1951;78(3):759–61.CrossRef
23.
Zurück zum Zitat Moore M. In vivo and in vitro effect of aureomycin hydrochloride on Syringospora (Monilia, Candida) albicans. J Lab Clin Med. 1951;37(5):703–12.PubMed Moore M. In vivo and in vitro effect of aureomycin hydrochloride on Syringospora (Monilia, Candida) albicans. J Lab Clin Med. 1951;37(5):703–12.PubMed
24.
Zurück zum Zitat Huppert M, MacPherson DA, Cazin J. Pathogenesis of Candida Albicans infection following antibiotic therapy. Department of Bacteriology and Immunology, University of North Carolina School of Medicine. 1952;65:171–6. Huppert M, MacPherson DA, Cazin J. Pathogenesis of Candida Albicans infection following antibiotic therapy. Department of Bacteriology and Immunology, University of North Carolina School of Medicine. 1952;65:171–6.
26.
Zurück zum Zitat Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub A. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gyn. 2019;220:324–36.CrossRef Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub A. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gyn. 2019;220:324–36.CrossRef
26.
Zurück zum Zitat Agnew KJ, Hillier SL. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis. 1995 Sep-Oct;22(5):269–73.CrossRef Agnew KJ, Hillier SL. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis. 1995 Sep-Oct;22(5):269–73.CrossRef
27.
Zurück zum Zitat Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol. 1996;34(10):2497–9.PubMedPubMedCentral Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol. 1996;34(10):2497–9.PubMedPubMedCentral
28.
Zurück zum Zitat St H, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infection. J Infect Dis. 1996;174:1058–63.CrossRef St H, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infection. J Infect Dis. 1996;174:1058–63.CrossRef
29.
Zurück zum Zitat Chetwin E, Manhanzva MT, Abrahams AG, Froissart R, Gamieldien H, Jaspan H, et al. Antimicrobial and inflammatory properties of South African clinical Lactobacillus isolates and vaginal probiotics. Sci Rep. 2019;9:1917.CrossRef Chetwin E, Manhanzva MT, Abrahams AG, Froissart R, Gamieldien H, Jaspan H, et al. Antimicrobial and inflammatory properties of South African clinical Lactobacillus isolates and vaginal probiotics. Sci Rep. 2019;9:1917.CrossRef
30.
Zurück zum Zitat Nichols RG, Peters JM, Patterson AD. Interplay between the host, the human microbiome, and drug metabolism. Hum Genomics. 2019;13(1):27.CrossRef Nichols RG, Peters JM, Patterson AD. Interplay between the host, the human microbiome, and drug metabolism. Hum Genomics. 2019;13(1):27.CrossRef
31.
Zurück zum Zitat Swidsinski A, Guschin A, Tang Q, Dörffel Y, Verstraelen H, Tertychnyy A, et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am J Obstet Gynecol. 2019 Jan;220(1):91.e1–8.CrossRef Swidsinski A, Guschin A, Tang Q, Dörffel Y, Verstraelen H, Tertychnyy A, et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am J Obstet Gynecol. 2019 Jan;220(1):91.e1–8.CrossRef
Metadaten
Titel
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure
verfasst von
Asmita Shukla
J. D. Sobel
Publikationsdatum
01.11.2019
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 11/2019
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-019-0700-y

Weitere Artikel der Ausgabe 11/2019

Current Infectious Disease Reports 11/2019 Zur Ausgabe

Transplant and Oncology (M Ison, N Theodoropoulos, and S Pergam, Section Editors)

CMV Prevention and Treatment in Transplantation: What’s New in 2019

Tropical, Travel and Emerging Infections (L Chen and A Boggild, Section Editors)

Yellow Fever in Travelers

Technology and Infectious Disease (C Hebert, Section Editor)

The Current and Future Use of Telemedicine in Infectious Diseases Practice

Tropical, Travel and Emerging Infections (L Chen and A Boggild, Section Editors)

Utility of 8-Aminoquinolines in Malaria Prophylaxis in Travelers

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.